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Treatment of membranes from guinea-pig peritoneal cosinophils with dcoxycholatc and NaCl solubilized ~95% of the particulate cyclic AMP- 
specific phosphodicsterase (PDE IV). Solubilizcd PDE IV was at least 10 times more potently inhibited by selective PDE IV inhibitors(e.g. roliprant, 
denbufyllinc) than bound enzyme. Vanadatclglutathionc complex (VGSH) activated mcmbranc-bound PDE IV and also increased potencies of 
these same inhibitors by at least IO-fold. Neither solubilization or V/GSH markedly influenced the inhibitory activities of non-xlcctivc inhibitors 
(e.g. trequinsin, dipyridamole), Inhibitor effects on solubilixcd PDE IV and cyclic AMP accumulirtion i intact cells wcrc strongly corrclatcd. Thcsc 
results suggest a biologically important site on cosinophil PDE IV which is conccalcd or partially conceulcd in freshly prcparcd membrdncs and 
is exposed by solubilixation or VIGSH. 
Cyclic AMP: Phosphodicsterusc; Eosinophil: Inhibitor 
1, INTRODUCTION 
Cyclic AMP-specific phosphodiesterase (PDE IV) is 
present in many inflammatory cells [l]. In guinea-pig 
eosinophils, PDE IV is the predominant and, perhaps, 
only PDE isozyme present with greater than 92% of the 
activity being tightly membrane-bound [2]. Inhibitors of 
PDE IV, alone, potently inhibit eosinophil superoxide 
(0”-) generation [2,3]. This effect occurs with a minimal 
elevation of intracellular cyclic AMP levels. although 
the order of potency of several PDE inhibitors in reduc- 
ing 0”’ generation correlates well with their effective- 
ness in increasing cyclic AMP accumulation when 
adenylate cyclase is stimulated with a p-agonist [2]. Sur- 
prisingly, inhibitor effects on membrane-bound cyclic 
AMP PDE and whole cell function (cyclic AMP/ 0”-) 
are poorly correlated [2]. For example, trequinsin is 
equipotent with rolipram and denbufylline in inhibiting 
the particulate PDE IV but is at least 100.fold less effec- 
tive than the latter two compounds in elevating cyclic 
AMP and reducing 0,2- generation. It was proposed 
that the entry of trequinsin into eosinophils is, some- 
how, hindered [2]; however, this explanation is difficult 
to reconcile with the fact that this compound is a very 
potent effector of other cell types 141. 
We have undertaken further studies on eosinophil 
PDE IV and demonstrated issimilar inhibitory actions 
of rolipram and trequinsin indicating different sites of 
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action which may explain the aforementioned anomo- 
lies. 
2. MATERIALS AND METHODS 
“Cyclic [2.8-‘HIAMP (41 Ci/mmol) and [S-‘HlGMP (13.8 Ciimmol) 
were purchased from Amcrshdm hernational (Amersham. Bucks.. 
UK). Rolipram [4-(3-cyclopentyloxy-4-mcthoxyphenyl)-2-pyrolidone~ 
and AH-21-132 [(+)-cb~6-0_acetamidopl~enyl)-1,2.3,4.4a,lOb-hexa- 
hydro-8.9.dimethoxy-2.mcthylbcnzo-{c} ( I,6lnaphthyridinc] wcrc 
synthesized by the Dcpartmcnt of Discovery Chemistry, Rhhc- 
Poulcnc Rorer Ltd. (Dagenham. Essex. UK). Dcnbufyllinc (BRL 
30892; I,3-di-a-butyl-7-[2’-oxopropyll-xanthine) was P gift from 
Bcccham Pharmaceuticals (Epsom. Surrey, UK). Trequin sin (HL-725: 
9.10~dimcthoxy-2~mcsitylimino-3-mcthyl-3,4,6,7-tetrahydr~2H-pyr- 
imido(dl-alisoquinolin4onc) was supplied by Hoc&t Pharmaceu- 
ticals (Hounslow, Middx.. UK). Ro-20.1724 [ 14(3-butoxy4 
methoxybcnnyl)-2.imidoxolidinone) was obtained from Roche Prod- 
ucts Ltd, (Wclwyn Garden City, UK). The cyclic AMP radioimmu- 
noassay kit was purchased from NEN Chemicals GmbH. All other 
chemicals were obtained from Sigmu Chemical Co.. BDH Chemicals 
(both of Poole. Doract. UK) and Rhdne-Poulcnc Ltd, 0%&S. Man- 
chester. UK). Male Dunkin Hartley guinea-pigs were purchased from 
a local supplier. 
2.2. Prepururicrk~ o~guinea-pig eosinophih orrd preporrrrion uJsuhceliu- 
far Jk~c.ticrtts 
Guinea-pig peritoneal cosinophils were purified and subcellular 
fractions prepared according to 121. 
2.3. SoluBikatiorr arrdparriui purt~carion oj cyrfic AMP PDE 
The membrane-bound cyclic AMP PDE was solubillzd by hornog- 
enizing freshly prepared mcmbrancs with a Douncc homogenizer (IO 
strokes) in 4 ml of homogenization buffer containing deoxycholatc 
(DDC) (0.5%) and NaCl (IO0 mM). The homogcnatc was ccntrifugcd 
at 100,000 x g for 30 min and the supcmatant containing the solubil- 
izcd activity removed and the Pellet resuspended in an equal volume 
of homogcnbzttisn buffer, 
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For partial purilication, I ml of solubilized cyclic AMP PDE activs 
ity containing 2-4 mg protein was applied IO 11 PD- IO desalting column 
(Pharmucia). The eluate was applied to a DEAE-trisacryl column (0.7 
x I cm) pre-equilibrutcd with column buffer (20 mM Tris-HCI, 2 mM 
MgCI:, I mM dithiothreitol, 20 /IM p-tosyl-L-lycine-chloromcthyl 
ketone. pH 7.5). The column was washed with IO ml ol’column bulYc1 
and PDE activities elutcd with a linear gradient 01’NaCl (O-O.7 M. I4 
ml) in column buffer, The flow rate was I ml~min-’ and I ml fraciiona 
were collected. 
2.4. Mtwsurtwtrttr of PDE curhit) 
PDE activity was determined according to [5]. The ICyI values 
(concentration which produced 50% inhibition of substrate hydroly- 
sis) for the compounds examined were determined from ccnccntra. 
tion-response curves in which concentrations ranged from 0.6 nM to 
I mM. At least three concentration-response curves were generated 
for each agent. For the determination of V,,,,, and K,,, WIUCS, the 
concentration ol’ cyclic AMP was varied while the amount of ‘H- 
labelled cyclic AMP remained consrant. The data were evaluated by 
an iterative procedure (computer program written by Dr. M. Vlitos, 
Computer Department, Rhdne-Poulenc Rorcr Lid.) for analysis 01 
complex kinetics [G]. 
Protein was dctermincd [7] with bovine strum ;Ilbumin as the stand- 
ard. Vanadate/glutathione complex (VGSH) was prcparcd and uddcd 
to enzyme assirys according to [B]. The nomenclature for cyclic nuclc- 
otidc PDE adopted in this paper is bused on [9]. 
Cell incubdons and mcasurcmcnt ofcyclic AMP was as dcscribud 
[2]. The E& values (concentration which produced 50% of maximal 
cyclic AMP response) for the compounds examined wcrc dctermincd 
from concentration-response curves in which conccntriltions ranged 
from 0.032 PM lo 500 PM. 
3. RESULTS 
3.1, Solrrbikation oj eosirtophiE pnrkwlare PDE IV 
Gentle homogenization (Dounce) of eosinophil mem- 
branes in buffer containing DOC (0.5%) (critical micelle 
concentration of DOC = 0,21%) and NaCl (100 mM) 
solubilized almost all (>95%) the cyclic AMP PDE ac- 
tivity. This treatment released less than 50% of the par- 
ticulate proteins. Solubilized PDE IV eked as a single 
Fraciion number 
Fig. I. DEAE-trisacryl chromatography of solubilizcd cyclic AMP 
PDE activity. Fractions were assayed for cyclic AMP PDE Ilctivity (I 
yM subslrale) in lhe presence of 200 PM EGTA, 
PDE (IC50 -loe,# 
Fig. 2. Siimulution of cyclic AMP accumulation i intact eosinophils 
as a function of inhibition of solubilized PDE IV. Eosinophil cyclic 
AMP dilla arc expressed as EC,, vulues (-log,,M) and cyclic AMP 
PDE dala (see Table I) as lCp, values (-log,,,M). Cyclic AMP and 
PDE studies were pcrformcd on ditl’crcnt preparations of cells. Each 
point is the mean of at leust 3 dctcrminutions. Regression analysis (Fig 
1’ computer program BIOSOFT) demonstrutcd that stimuladon of 
cyclic AMP accumulation as a funclion of PDE IV inhibitory activity 
is highly significant (r=0.97, P<O,OOl, rt=G), The symbols represent 
rolipram (0). dcnbufyllinc (~31, Ro.20~1724 (a), trequinsin (A), AH- 
21.132 (a) and IBMX (0). 
peak from DEAE-trisac:yl at a NaCl concentration of 
300 mM (Fig. 1.). 
3.2. hhibiror potemy againsr scfubilked PDE IV 
Rolipram, denbufylline and Ro-20-1724 potently in- 
hibited solubilized PDE IV (Table I). The inhibitory 
potencies of these compounds were at least IO-fold 
greater than against the bound, particulate nzyme. In 
contrast. a number of other, non-selective PDE inhib- 
itors (trequinsin, AH-21-132, dipyridamole, 3-isobutyl- 
l-methyl xanthine (IBMX)) exhibited similar inhibitory 
potencies against he bound and solubilized eosinophil 
PDE IV (Table I). Regression analysis of the relation- 
ship between the inhibitory potencies (I&‘s PM) of 
Table I 
Inhibitor potencies agains\ bound and solubilized particulate PDE IV 
from cosinophils. Eosinophil bound and solubilired DDE IVs were 
measured with I /M substrate 
Inhibitor 
ICY, WM) 
Eosinophil PDE IV 
Bound Solubilized 
Rolipran: 0.23 + 0.02 (If= 10) 0,014 * 0.003 (,r=9) 
Dipyridamolc 8.1 I! I.4 (II= 8) 5.0 2 0.58 (s=3) 
Trequinsin 0.36 f 0.08 (It= 9) 0.89 2 0.20 (n=B) 
AH-21-132 3.4 1 I.2 (It= 4) 1.3 ?I 0.31 (rt=3) 
Dunbufyllinc 0.36 + 0.08 (II= 6) 0.035 rt: 0.009 (r?=4) 
Ro-20. I724 0.92 i: 0.35 (II= 3) 0,083 ‘r 0.023 (n=3) 
IBMX 4.8 If: I.6 (It= 3) 5.3 + 2.3 (/I=31 
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Fig. 3. Inhibition o~boulld, ~~rticul~t~cyc~i~ AMP PDE by rolipr~n~, 
denbufyllinc. trequinsin and dipyrid~nlo~~ in the presence and absence 
of YIGSH. PDE activity assayed in the prcscncc of the indicutcd 
conccntretionS of roliprtim (panel A). trequinsin (panel 9). dcnbufyi- 
line (panel C) and dipyridamolc (pan4 D) with (B) and without (@) 
VGSH. The results represent the means f. S.E.M. of between 3and 
5 expcrimems. 
inhibitors against solubilized PDE IV and their efficu- 
ties in elevating cyclic AMP levels in intact cells (EC,,% 
yM) indicated a very strong (r-0.97, P~O.001, rr=6) 
correlation (Fig. 2,). inhibitor effects on bound, partic- 
ulate PDE IV and cyclic AMP accumulation were rela- 
tively weakly correlated (r=0.63, P=O. i 8, n=6). 
Exposure of eosinophil membranes to NaJVO, (1.4 
mM) and GSH (2.8 rnM) (V/GSH), which has previ- 
ously been shown to activate membrane-bound, 
hormone-sensitive PDE III in adipocptes and hepato- 
cytes [&lo], caused a large, reversible stimulation of 
cyclic AMP PDE activity. Neither Na,VC, nor GSH, 
when added alone, influg~~~ activity. As reported pre- 
viously 121, the bound particulate osinophil PDE exhib- 
ited complex kinetics. Analysis of the data [6] revealed 
K, values of 1 yM and 40 PM for the high- and low- 
affinity components, respectively. V/GSH did not 
greatly influence the K,, values (3 PM and 48 PM) but 
the v,,, values were greatly increased (0.05 and 0.4 
nmoi~nlm-‘*m!-‘, without V/c-S!-!; 0.4 and 2 
nmolmin-‘*ml-‘, with V/CSH). The V/GSH-induced 
stimulation of PDE IV activity was oniy observed in 
membranes prepared from freshly isolated eosinophils; 
the bound, parti~uiate PDE in membrane from cells 
stored frozen (-70°C) for i day or longer was inhibits 
by VtGSH. 
Solubilized PDE IV also exhibited non-linear kinetics, 
but the affinity of the enzyme for substrate (K,.,,s=22jlM 
and 101 yM) was reduced in comparison to the bound, 
particulate enzyme while the VWr values (0.3 and 3 
nmolamin-‘#ml-‘) were greatly increased. V/GSH ex- 
erted a much smaller effect on the solubilized PDE eom- 
pared to the bound, particulate activity. Substrate affin- 
ities (I&s= 13 PM and 134 PM) and V,, values (0.4 and 
4 nmol~min-l~ml-‘) were marginally in~rea~d by VI 
GSH. VlGSH had no effect on partially purifi~ solubil- 
ized PDE IV. 
3.4. EjJert of’ V/GSH 012 Bhibitor potency 
Exposure of cosinophil membranes to V/GSH in- 
creased the inhibitory potencies of rolipram 
(&‘s=O.24 Z!Z 0.12 FM, )I=$ without V/GSH; 
0.02 + 0.01 PM, tr=5 with V/GSH) and denbufylline 
(lCW’s=0.29 +0,16 ,uM. r1=3, without V/GSH; 
0.02 & 0.01 PM, 1~3, with V/GSH) by approximately 
10.fold. In contrast V/GSH only slightly increased the 
potency of treq~illsin (1C5,‘s=0.32 + 0.09 PM, n=S, 
witllo~t VIGSH; 0.2 + 0.05,&i, it=% with VIGSH) and 
the KS, value of dipyridamole (8f 1.2 ,uM, n=3) was 
unaffected (Fig. 3). in contrast to the rese!ts obtained 
on the bound enzyme, V/GSH had no effect on tin? 
inhibitory potency of rolipram on solubilized PDE IV. 
Trcquinsin also exhibited similar inhibitory potencies 
against solubilized PDE IV in the absence and presence 
of V/GSH (data not shown). 
4. DISCUSSION 
In view of the evidence suggesting only one cyclic 
AMP PDE (ref f2f. Fig. 1). a possible explanation for 
differences in the inhibitory actions of selective PDE 1V 
inhibitors and non-selective inhibitors requires invoking 
the existence of two sites on the enzyme. The rolipram 
group of compounds, at high concentrations, and the 
trequinsin group both interact at a site (perhaps the 
catalytic site) which is designated SC. Rolipram and 
other PDE IV inhibitors, as well as acting at SC, can also 
potently interact at a second site which is designated Sr. 
In freshly prepared membranes, rolipram and trequin- 
sin would act pr~ominant~y atSC with Sr being inacccs- 
sible or only partially accessible. V/GSH, acting indi- 
rectly, by inducing a confo~ational change in the 
bound, particulate nzyme. would expose Sr so increas- 
ing the potencies of selective PDE IV inhibitors. Solubil- 
ization would also expose Sr explaining why V/GSH did 
not influence rolipram potency on liberated activity. 
The poor correlation between intracellular cyciic 
AMP accumulation and inhibitor actions on untreated 
membrane-bound PDE IV indicates, perhaps, that the 
enzyme is not naintained in its native form following 
183 
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cell disruption. In contrast. a very strong correlation [a] Ruppert. D. and Wcithmann. K.U. (1982) Life Sci. 31, 2037- 
was demonstrated between I&, values of inhibitors 2043. 
against solubilized PDE IV and their potencies in ele- [S] Thompson, W.J., Terasaki, W,, Epstein, P.M. und Strada, S,J, 
vating intracellular cyclic AMP implying that, in intact (1979) Adv. Cyclic Nucleotidc Rcs. IO, 69-92, 
eosinophils, cyclic AMP PDE exists in a form similar 
161 Spears, G., Sneyd, J,G.T. and Lolcn. E.G. (1971) Biochem. J. 
125, 1149-l 151. 
to the solubilized or V/GSH-treated -enzyme. Further- 
more, it suggests the potential importance of the puta- 
tive Sr in regulating eosinophil function. 
Finally, several studies [l I-131 indicate that the bio- 
logical actions of rolipram result from a relatively weak, 
[7] Lowry, Q.H.. Roscbrouyh, NJ,. Farr, A.L. and Randall, R.J. 
(1951) J. Biol. Chem. 193, 265-275. 
181 SOUIICSS. J,E.. Thompson, W.J, and Strada. S,J, (1985) J, Cyclic 
Nucleotide Protein Phosphorylation Rcs, IO, 383-396. 
[9] Bravo. J.A. und Rcifsnydcr. D.H. (1990) Trends Pharmacol. Sci. 
I I, 150-155. 
competitive inhibition of PDE IV. Our results suggest 
that a reappraisal of this view is warranted. 
[IO] Thompson, W.J., Tun, B.H. and Strada. S.J. (1991) J. Biol. 
Chcm. 2G6. 1701 l-17019. 
[I I] Reeves, M,L.. Leigh, B.K. and England, P,J, (1987) Biochem. J, 
241, 535-541. 
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